Clarify DL

The Clarify DL device is a software-only Class II medical device designed to enhance Nuclear Medicine bone SPECT scintigraphy images by reducing noise and improving clarity, applicable to patients of all ages. Its substantial equivalence to existing devices was demonstrated through comprehensive non-clinical bench testing and clinical reader evaluations, confirming equivalent diagnostic quality via its image processing capabilities, implicitly leveraging deep learning technology.

The Clarify DL device, developed by GE Medical Systems Israel, Functional Imaging, has received a determination of substantial equivalence to legally marketed medical devices as of January 3, 2025. This software-only, Class II medical device, categorized as a Medical Image Management and Processing System, is designed to enhance the quality of Nuclear Medicine bone SPECT scintigraphy images by reducing noise and improving clarity, and is indicated for use across all patient ages. The finding of substantial equivalence was supported by comprehensive non-clinical and clinical testing, confirming that its technological characteristics do not introduce new safety or effectiveness concerns and that it produces images of equivalent diagnostic quality compared to its predicate devices. The evaluation included extensive bench testing for image and lesion characteristics and a clinical reader evaluation by expert physicians. The device also incorporates a Predetermined Change Control Plan, allowing certain modifications without new submissions if they adhere to the plan and do not significantly affect safety or effectiveness, with ongoing marketing subject to continuous compliance with general controls and regulations.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the deep learning algorithm within Clarify DL specifically achieve noise reduction and clarity improvement without sacrificing diagnostic information?; What were the specific metrics used in bench testing to evaluate image and lesion characteristics, and how did Clarify DL perform against predicate devices?; Are there specific types of bone SPECT pathologies or patient populations where Clarify DL's benefits are most pronounced or, conversely, less effective?; What are the limitations of the Predetermined Change Control Plan regarding future modifications, and what types of changes would necessitate a new FDA submission?; Have long-term studies or post-market surveillance data shown any impact of using Clarify DL on diagnostic confidence or patient outcomes beyond image quality?